CHEMOS
Applications

Hepatocyte-Targeted Delivery

GalNAc ligands, oligo conjugation handles, lipid conjugates, and linker choices for liver-directed delivery research.

Back to Applications

How this supports a project

For the GalNAc-ASGPR route, the material specification must define ligand architecture and valency, oligonucleotide attachment position, linker, synthesis route, and conjugate confirmation.

Define the conjugate, not only the target tissue

Multivalent GalNAc ligands have been studied for receptor-mediated uptake through the asialoglycoprotein receptor (ASGPR) on hepatocytes. Published ASO and siRNA work also shows that ligand architecture, valency, scaffold, attachment site, and oligonucleotide chemistry can change conjugate behavior.

A project should therefore specify the exact GalNAc construct and oligonucleotide connection. “Liver targeted” is not a chemical identity, and evidence from one conjugate cannot be transferred automatically to a different sequence, format, linker, or ligand presentation.

How material decisions enter the program

1

Define the oligonucleotide

Record sequence, strand format, modification map, backbone pattern, termini, and the proposed GalNAc attachment position.

2

Choose the GalNAc architecture

Specify mono- or multivalent design, preassembled cluster or monomer-based assembly, scaffold, and stereochemical identity where relevant.

3

Design the connection

Define attachment site, spacer length and composition, linkage chemistry, and stability or release requirements.

4

Select the installation route

Decide whether the ligand is introduced through a functionalized solid support, during solid-phase assembly, or by post-synthetic conjugation.

5

Purify and confirm the conjugate

Separate unconjugated or partially modified material and confirm oligonucleotide identity, ligand incorporation, conjugate mass, and purity.

6

Verify receptor-dependent performance

Use appropriate controls to test ASGPR-dependent uptake and functional oligonucleotide activity in the intended model.

What to define before an inquiry

Oligonucleotide format

State ASO, siRNA strand, or other format, together with sequence, modifications, termini, and conjugation position.

GalNAc identity and valency

Provide the exact ligand or scaffold rather than using GalNAc as a generic product name.

Linker and attachment chemistry

Specify spacer, linkage, reaction handle, orientation, and compatibility with synthesis and deprotection.

Installation route

Define on-support, on-strand, or post-synthetic installation and the required protected intermediates or functional handles.

Analytical and biological controls

Define conjugate identity and purity tests plus unconjugated, competition, or receptor-dependence controls as appropriate.

Application boundary

This page covers chemistry and material planning for GalNAc-oligonucleotide research. It does not establish hepatocyte uptake, in vivo distribution, silencing activity, dose, safety, clinical suitability, or regulatory status for a proposed conjugate.

Related catalog and technical pages

Oligo conjugation and delivery ligandsBrowse GalNAc ligands, attachment handles, lipid conjugates, cholesterol derivatives, and related linkers.Oligonucleotide synthesis and modification materialsBrowse modified phosphoramidites, solid supports, sulfurizing reagents, and strand-synthesis inputs.Oligonucleotide modification platformReview the CHEMOS scope for terminal handles, solid-support choices, conjugation, and modified strands.siRNA research programsReview strand-by-strand modification and conjugation requirements for siRNA research.GalNAc versus lipid conjugationCompare the material and attachment questions raised by two different oligonucleotide-delivery routes.

Sources

  1. 1.Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency in mice (Nucleic Acids Research, 2014)
  2. 2.Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits RNAi-mediated gene silencing (Journal of the American Chemical Society, 2014)
  3. 3.Novel Cluster and Monomer-Based GalNAc Structures Induce Effective Uptake of siRNAs In Vitro and In Vivo (Molecular Therapy - Nucleic Acids, 2018)
  4. 4.Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression (Molecular Therapy - Nucleic Acids, 2018)